Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male Age 45 or older~* Histologically confirmed adenocarcinoma of the prostate~* Disease Staging III or IV~* Clinical indication for androgen suppression therapy~* Serum testosterone at least 150 ng/dL at screening~* WHO Performance Scale 0 to 3~* Life expectancy of at least one year~Key Exclusion Criteria:~* Bilateral orchiectomy~* Prior androgen-ablative therapy within past year~* Second malignancy with 5 years (except adequately treated non-melanomatous skin cancer or superficial bladder cancer)~* Spinal cord compression

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- one histrelin acetate 50 mg implant (Type: EXPERIMENTAL): The test product was a histrelin acetate 50 mg hydrogel implant surgically placed subdermally into the inner aspect of the upper arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).